Related Experiment Videos
Drug interactions with the taxanes
1Department of Pharmacology, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78284-6220, USA.
Abstract:
Interactions may occur when the taxanes paclitaxel and docetaxel are given concurrently with other drugs. Altered clearance may be expected because these agents are extensively metabolized by hepatic cytochrome P-450 enzymes, particularly isoenzymes 3A and 2C. Pharmacodynamic interactions that alter the molecular target or pharmacology of a drug may depend on the sequence or schedule of administration. Paclitaxel clearance is reduced when cisplatin precedes paclitaxel, although cisplatin does not affect the metabolism of paclitaxel by human liver microsomes. Measurement of DNA adduct levels in peripheral white blood cells indicates that a pharmacodynamic interaction may occur between cisplatin and both taxanes. The pharmacokinetics of carboplatin and paclitaxel were not altered when the drugs were given in combination; however, a pharmacodynamic interaction may explain the decreased frequency of thrombocytopenia compared with single-agent carboplatin. When paclitaxel precedes cyclophosphamide, myelosuppression is more severe. In contrast, when docetaxel precedes ifosfamide, toxicity is reduced. The mechanisms for these effects is unknown. With combination paclitaxel and doxorubicin regimens, the schedule of paclitaxel and the sequence of the agents may result in both pharmacokinetic and pharmacodynamic interactions.
Insights
Taxanes like paclitaxel can interact with other chemotherapy drugs, affecting how the body processes them. Drug sequencing and timing are crucial for managing these complex interactions and potential toxicities.
Area of Science:
- Oncology
- Pharmacology
- Drug Interactions
Background:
- Taxanes (paclitaxel, docetaxel) are metabolized by cytochrome P-450 enzymes, suggesting potential drug interactions.
- Drug interactions with taxanes can be pharmacokinetic (affecting clearance) or pharmacodynamic (affecting drug targets).
- The sequence and schedule of drug administration can influence the nature and severity of taxane-related interactions.
Purpose of the Study:
- To review potential pharmacokinetic and pharmacodynamic interactions of taxanes (paclitaxel, docetaxel) when co-administered with other chemotherapy agents.
- To highlight the impact of drug sequencing and scheduling on taxane efficacy and toxicity.
- To discuss observed interactions with specific drug combinations, including cisplatin, carboplatin, cyclophosphamide, ifosfamide, and doxorubicin.
Main Methods:
- Literature review of studies investigating taxane drug interactions.
- Analysis of pharmacokinetic data (drug clearance, metabolism) and pharmacodynamic data (DNA adducts, toxicity profiles).
- Examination of clinical outcomes related to concurrent taxane administration and varying schedules.
Main Results:
- Paclitaxel clearance is reduced when preceded by cisplatin, with evidence of a pharmacodynamic interaction.
- No pharmacokinetic alteration of carboplatin and paclitaxel, but a pharmacodynamic interaction may explain reduced thrombocytopenia.
- Combination therapy with paclitaxel and doxorubicin can lead to both pharmacokinetic and pharmacodynamic interactions depending on the schedule and sequence.
Conclusions:
- Concurrent administration of taxanes with other chemotherapy agents can lead to significant drug interactions.
- Drug metabolism via cytochrome P-450 enzymes and interactions at the molecular target level are key mechanisms.
- Careful consideration of drug sequencing and scheduling is essential to optimize treatment outcomes and minimize toxicity when using taxanes in combination regimens.